Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 5/2011

01-10-2011

Familial Mediterranean Fever and Seronegative Arthritis

Authors: Nurullah Akkoc, Ahmet Gul

Published in: Current Rheumatology Reports | Issue 5/2011

Login to get access

Abstract

Familial Mediterranean fever (FMF) is characterized by recurrent, self-limited episodes of polyserositis, with articular involvement also being a common manifestation. The pattern and joint predilection of arthritis show many similarities to those of spondyloarthritis. Moreover, case series suggest an increased prevalence of ankylosing spondylitis or spondyloarthritis among FMF patients. FMF is caused by mutations in the MEFV gene encoding pyrin, which is believed to be involved in regulation of interelukin-1β activation. Recent studies conducted in populations with a high background carrier rate of MEFV variants have reported an increased frequency of M694V among AS patients with no personal or family history of FMF. These findings are of interest, as both candidate gene and genome-wide association studies suggest that the interleukin-1 cytokine pathway may be implicated in the pathogenesis of ankylosing spondylitis. Therefore, association of M694V with ankylosing spondylitis can be recognized as a geographic region–specific risk factor affecting a common inflammatory pathway in the disease pathogenesis.
Literature
1.
2.
French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17:25–31.CrossRef
3.
International FMF. Consortium: Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell. 1997;90:797–807.CrossRef
4.
•• Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol. 2009, 27:621–668. The authors in this review proposed an updated classification for hereditary and acquired forms of autoinflammatory disorders based on molecular pathophysiology. FMF and AS are both included but in different categories. PubMedCrossRef
5.
6.
Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet. 2001;9:473–83.PubMedCrossRef
7.
• Marek-Yagel D, Bar-Joseph I, Pras E, Berkun Y. Is E148Q a benign polymorphism or a disease-causing mutation? The Journal of Rheumatology 2009, 36:2372. The authors extracted the data on E148Q from four published studies and found no difference between the Israeli controls and FMF patients. PubMedCrossRef
8.
Heller H, Gafni J, Michaeli D, et al. The arthritis of familial Mediterranean fever (FMF). Arthritis Rheum. 1966;9:1–17.PubMedCrossRef
9.
Garcia-Gonzalez A, Weisman MH. The arthritis of familial Mediterranean fever. Semin Arthritis Rheum. 1992;22:139–50.PubMedCrossRef
10.
Majeed HA, Rawashdeh M. The clinical patterns of arthritis in children with familial Mediterranean fever. QJM. 1997;90:37–43.PubMed
11.
Brik R, Shinawi M, Kasinetz L, Gershoni-Baruch R. The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum. 2001;44:1416–9.PubMedCrossRef
12.
Sneh E, Pras M, Michaeli D, et al. Protracted arthritis in familial Mediterranean fever. Rheumatol Rehabil. 1977;16:102–6.PubMedCrossRef
13.
Kaushansky K, Finerman GA, Schwabe AD. Chronic destructive arthritis in familial Mediterranean fever: the predominance of hip involvement and its management. Clin Orthop Relat Res. 1981:156–161.
14.
Salai M, Langevitz P, Blankstein A, et al. Total hip replacement in familial Mediterranean fever. Bull Hosp Jt Dis. 1993;53:25–8.PubMed
15.
Brik R, Shinawi M, Kepten I, et al. Familial Mediterranean fever: clinical and genetic characterization in a mixed pediatric population of Jewish and Arab patients. Pediatrics. 1999;103:e70.PubMedCrossRef
16.
Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84:1–11.CrossRef
17.
Cefle A, Kamali S, Sayarlioglu M, et al. A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis. Rheumatol Int. 2005;25:442–6.PubMedCrossRef
18.
Dilsen N. [Familial Mediterranean fever (periodic disease) associated with ankylopoietic spondylitis. (Apropos of a case)]. Turk Tip Cemiy Mecm. 1963;29:160–7.PubMed
19.
Dilsen NA. Ankylosing spondylitis in familial Mediterranean fever (periodic disease). Excerpta Medica Intern Congr ser. 1973;299:107.
20.
Yazici H, Turunc M, Ozdogan H, et al. Observer variation in grading sacroiliac radiographs might be a cause of ‘sacroiliitis’ reported in certain disease states. Ann Rheum Dis. 1987;46:139–45.PubMedCrossRef
21.
Brodey PA, Wolff SM. Radiographic changes in the sacroiliac joints in familial Mediterranean fever. Radiology. 1975;114:331–3.PubMed
22.
Langevitz P, Livneh A, Zemer D, et al. Seronegative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum. 1997;27:67–72.PubMedCrossRef
23.
• Baraliakos X, Listing J, von der Recke A, Braun J. The natural course of radiographic progression in ankylosing spondylitis—evidence for major individual variations in a large proportion of patients. Rheumatol. 2009, 36:997–1002. This study indicates that radiographic progression in AS is rather variable, and the authors propose to differentiate patients as fast, moderate, and slow radiographic progressors based on development of new syndesmophytes over time.PubMedCrossRef
24.
Boonen A, vander Cruyssen B, de Vlam K, et al. Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J Rheumatol. 2009;36:1249–55.PubMedCrossRef
25.
Nash P, Mease PJ, Braun J, van der Heijde D. Seronegative spondyloarthropathies: to lump or split? Ann Rheum Dis. 2005;64 Suppl 2:ii9–13.PubMedCrossRef
26.
Younes M, Kahn MF, Meyer O. Hip involvement in patients with familial Mediterranean fever. A review of ten cases. Joint Bone Spine. 2002;69:560–5.PubMedCrossRef
27.
•• Kasifoglu T, Calisir C, Cansu DU, Korkmaz C. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol. 2009, 28:41–46. This study investigated the presence of sacroiliitis among FMF patients using MRI of the sacroiliac joints in addition to conventional radiography, and found a higher-than-expected prevalence of sacroiliitis. Almost all patients with FMF and sacroiliitis carried at least one allele of the M694V variant.PubMedCrossRef
28.
Akar S, Soysal O, Yuksel F, et al. High prevalence of axial spondyloarthritis in patients with familial Mediteranean fever, and a greater allelic frequency of M694V in familial Mediteranean fever patients with radiograpic sacroiliitis. Arthritis Rheum. 2010;62:S278.
29.
Knockaert DC, Malysse IG, Peetermans WE. Ankylosing spondylitis. An unusual manifestation of familial Mediterranean fever. Report of a case complicated by amyloidosis and polyneuropathy. Clin Rheumatol. 1989;8:408–12.PubMedCrossRef
30.
Sari I, Simsek I, Guvenc I, et al. Osteopoikilosis coexistent with ankylosing spondylitis and familial Mediterranean fever. Rheumatol Int. 2009;29:321–3.PubMedCrossRef
31.
Duman I, Balaban B, Tugcu I, Dincer K. Familial mediterranean fever unusually coexisted in an ankylosing spondylitis patient. MEFV mutation has any role? Rheumatol Int. 2007;27:689–90.PubMedCrossRef
32.
Kaushik P, el-Sobkie NI, Shehab D, Malaviya AN. Familial Mediterranean fever with HLA B-27 positive ankylosing spondylitis in a young Armenian man. Clin Exp Rheumatol. 1999;17:387–8.PubMed
33.
Keles I, Aydin G, Tosun A, et al. Familial Mediterranean fever and ankylosing spondylitis in a patient with juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int. 2006;26:846–51.PubMedCrossRef
34.
Akar S, Birlik M, Sari I, et al. M694V mutation may have a role in susceptibility to ankylosing spondylitis. Rheumatol Int. 2009;29:1259–60.PubMedCrossRef
35.
•• Cosan F, Ustek D, Oku B, et al. Association of familial Mediterranean fever-related MEFV variations with ankylosing spondylitis. Arthritis Rheum. 2010, 62:3232–3236. This study reported a significantly higher frequency of M694V among AS patients with no personal or family history of FMF as compared with healthy controls.PubMedCrossRef
36.
•• Akkoc N, Sari I, Akar S, et al. Increased prevalence of M694V in patients with ankylosing spondylitis: additional evidence for a link with familial Mediterranean fever. Arthritis Rheum. 2010, 62:3059–3063. This study reported a significantly higher frequency of M694V among AS patients than in healthy controls and patients with rheumatoid arthritis.PubMedCrossRef
37.
Durmus D, Alayli G, Cengiz K, et al. Clinical significance of MEFV mutations in ankylosing spondylitis. Joint Bone Spine. 2009;76:260–4.PubMedCrossRef
38.
Akkoc N, Gul A. Comment on the article by Durmus et al. “Clinical significance of MEFV mutations in ankylosing spondylitis”. Joint Bone Spine. 2010;77:281.PubMedCrossRef
39.
Cinar M, Dinc A, Simsek I, et al. The rate and significance of Mediterranean fever gene mutations in patients with ankylosing spondylitis: a three-month, longitudinal clinical study. Rheumatol Int. 2008;29:37–42.PubMedCrossRef
40.
Maras Y, Calguneri M, Akdogan A, et al. MEFV mutations frequency and effect on disease severity in ankyloing spondylitis EULAR Meeting Abstracts. 2007, 66:400.
41.
•• Reveille JD. The genetic basis of spondyloarthritis. Ann Rheum Dis. 2011, 70 Suppl 1:i44-50. This is a very comprehensive review on the genetics of AS.PubMedCrossRef
42.
Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39:1329–37.PubMedCrossRef
43.
•• Reveille JD, Sims AM, Danoy P, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010, 42:123–127. This recent genome-wide association study confirmed the strong association of the HLA-B region and also revealed several non-HLA susceptibility genes for AS.PubMedCrossRef
44.
Sims AM, Timms AE, Bruges-Armas J, et al. Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann Rheum Dis. 2008;67:1305–9.PubMedCrossRef
45.
Carter KW, Pluzhnikov A, Timms AE, et al. Combined analysis of three whole genome linkage scans for ankylosing spondylitis. Rheumatology (Oxford). 2007;46:763–71.CrossRef
46.
•• Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010, 10:89–102. This paper provided a very comprehensive review of the IL-1 family in health and disease.PubMedCrossRef
47.
Chae JJ, Wood G, Richard K, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood. 2008;112:1794–803.PubMedCrossRef
48.
Yu JW, Wu J, Zhang Z, et al. Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ. 2006;13:236–49.PubMedCrossRef
49.
Papin S, Cuenin S, Agostini L, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 2007;14:1457–66.PubMedCrossRef
50.
Waite AL, Schaner P, Hu C, et al. Pyrin and ASC co-localize to cellular sites that are rich in polymerizing actin. Exp Biol Med (Maywood). 2009;234:40–52.CrossRef
51.
Shiohara M, Taniguchi S, Masumoto J, et al. ASC, which is composed of a PYD and a CARD, is up-regulated by inflammation and apoptosis in human neutrophils. Biochem Biophys Res Commun. 2002;293:1314–8.PubMedCrossRef
52.
Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417–26.PubMedCrossRef
53.
Dowds TA, Masumoto J, Chen FF, et al. Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product. Biochem Biophys Res Commun. 2003;302:575–80.PubMedCrossRef
54.
Stehlik C, Lee SH, Dorfleutner A, et al. Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol. 2003;171:6154–63.PubMed
55.
Lachmann HJ, Sengul B, Yavuzsen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45:746–50.CrossRef
56.
• Booty MG, Chae JJ, Masters SL, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum. 2009, 60:1851–1861. This study described patients with classical features of FMF despite a single MEFV mutation.PubMedCrossRef
57.
Ustek D, Ekmekci C, Oku B, et al. MEFV gene 3′-UTR Alu repeat polymorphisms in patients with familial Mediterranean fever. Clin Exp Rheumatol. 2008;26:S72–6.PubMed
58.
• Ben-Chetrit E, Peleg H, Aamar S, Heyman SN. The spectrum of MEFV clinical presentations—is it familial Mediterranean fever only? Rheumatology (Oxford). 2009, 48:1455–1459. This study discusses the atypical autoinflammatory clinical features in patients carrying MEFV variations.CrossRef
59.
Kone-Paut I, Hentgen V, Guillaume-Czitrom S, et al. The clinical spectrum of 94 patients carrying a single mutated MEFV allele. Rheumatology (Oxford). 2009;48:840–2.CrossRef
60.
Touitou I, Magne X, Molinari N, et al. MEFV mutations in Behcet’s disease. Hum Mutat. 2000;16:271–2.PubMedCrossRef
Metadata
Title
Familial Mediterranean Fever and Seronegative Arthritis
Authors
Nurullah Akkoc
Ahmet Gul
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 5/2011
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-011-0191-9

Other articles of this Issue 5/2011

Current Rheumatology Reports 5/2011 Go to the issue

ReviewPaper

Mucosal Inflammation in Spondylarthritides: Past, Present, and Future

ReviewPaper

Environmental Exposures and Rheumatoid Arthritis Risk

ReviewPaper

Pathophysiology of Spondyloarthritis

Clinical Trial Report

Inhibition of Spleen Tyrosine Kinase for Rheumatoid Arthritis

ReviewPaper

Synovial Tissue Heterogeneity and Peripheral Blood Biomarkers

ReviewPaper

Pregnancy and Rheumatoid Arthritis: Insights into the Immunology of Fetal Tolerance and Control of Autoimmunity
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits